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METHODOLOGY Open Access
The use of qualitative methods to inform
Delphi surveys in core outcome set
development
T. Keeley1*, P. Williamson2, P. Callery3, L. L. Jones1, J. Mathers1, J. Jones1, B. Young4 and M. Calvert1
Abstract
Background: Core outcome sets (COS) help to minimise bias in trials and facilitate evidence synthesis. Delphi surveys
are increasingly being used as part of a wider process to reach consensus about what outcomes should be included in
a COS. Qualitative research can be used to inform the development of Delphi surveys. This is an advance in the field of
COS development and one which is potentially valuable; however, little guidance exists for COS developers on how
best to use qualitative methods and what the challenges are. This paper aims to provide early guidance on the
potential role and contribution of qualitative research in this area. We hope the ideas we present will be challenged,
critiqued and built upon by others exploring the role of qualitative research in COS development.
This paper draws upon the experiences of using qualitative methods in the pre-Delphi stage of the development of
three different COS. Using these studies as examples, we identify some of the ways that qualitative research might
contribute to COS development, the challenges in using such methods and areas where future research is required.
Results: Qualitative research can help to identify what outcomes are important to stakeholders; facilitate
understanding of why some outcomes may be more important than others, determine the scope of outcomes;
identify appropriate language for use in the Delphi survey and inform comparisons between stakeholder data
and other sources, such as systematic reviews. Developers need to consider a number of methodological points
when using qualitative research: specifically, which stakeholders to involve, how to sample participants, which
data collection methods are most appropriate, how to consider outcomes with stakeholders and how to analyse
these data. A number of areas for future research are identified.
Conclusions: Qualitative research has the potential to increase the research community’s confidence in COS,
although this will be dependent upon using rigorous and appropriate methodology. We have begun to identify
some issues for COS developers to consider in using qualitative methods to inform the development of Delphi
surveys in this article.
Keywords: Core outcome sets, Qualitative research, Delphi, Methodology, Clinical trial
Background
Randomised controlled trials (RCTs) typically provide
robust evidence, which can be used to inform clinical
practice and health policy [1]. The outcomes measured
within a RCT allow the benefits (or harms) associated
with an intervention to be quantified. Outcomes mea-
sured in RCTs need to be useful and relevant to a range
of stakeholders including patients, clinicians, policy-
makers and regulatory agencies [2, 3]. Outcomes are
often identified, chosen and specified a priori by the trial
management team (traditionally, researchers and clini-
cians), sometimes with input from patient and public
contributors [4].
The use of numerous varying trial outcomes across a
research field or clinical area can be problematic. First,
this can reduce the ability of systematic reviewers to syn-
thesise results. The most accessed Cochrane reviews of
2009 all reported problems with heterogeneity of out-
comes [5], while similar problems were found in an
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analysis of the ClinicalTrials.gov database [6]. Second,
lack of an accepted standard can lead to reporting bias,
based on the significance of the findings [7–9]. Further-
more, outcomes that are selected solely by researchers
or clinicians may not hold relevance for other stake-
holders, such as patients, carers or other decision-
makers.
These problems can be addressed through the devel-
opment of a core outcome set (COS) for use in a clinical
area or research field. A COS is a standardised collection
of outcome domains that should be reported in all con-
trolled trials within a research area [10]. Trialists are not
restricted solely to these outcomes and can use add-
itional outcomes to those in the core set; therefore, a
COS marks the basic requirement for which outcomes
need to be measured and reported in all studies in a field
[11]. Furthermore, COS development is typically fo-
cussed initially on what to measure with subsequent
consideration needed of how to measure those core out-
comes. In this paper we use the term ‘outcome’ to refer
to outcome domains.
The rate of development of COS has increased over the
last 10 years, to the point where close to 20 new COS
were published in 2013 [12]. Core outcome sets have been
developed for use in a wide variety of clinical specialties
[13], including cancer, rheumatology, neurology and car-
diorespiratory research; for use with different populations,
such as adults and children; and for use specifically in
pharmaceutical or surgical research. The development of
COS is attractive to funders such as the National Institute
for Health Research (NIHR) and others, as it increases the
chance that the ‘value of their investments will be greater
than the sum of the reports’, through the increased ability
to synthesise and compare results, as well as a greater
assurance the that outcomes used in funded studies will
be of relevance to stakeholders [14].
The methods used in COS development exercises are
important as they may influence the final COS [3].
Development of a COS can comprise several phases,
often starting with a systematic review of the published
literature to identify what outcomes have been measured
in previous trials or studies in a clinical area. This may
generate a ‘long list’ of candidate outcomes for a COS.
Consensus methods, such as simple face-to-face meet-
ings, nominal group techniques and, increasingly, the
Delphi survey, may then be used to reach agreement
about which outcomes are ‘core’ [3, 13]. The Delphi is
often followed by a consensus meeting of key stake-
holders to agree the final COS. Qualitative research can
be used in several of these phases, but our main focus in
this paper is to outline the use of qualitative research to
inform Delphi surveys in COS development.
A Delphi survey is a sequential process through which
the opinions of participants are sought, usually
anonymously [11]. Participants in a Delphi survey do
not interact directly; rather, after the completion of each
round of questionnaires, the collated group responses
are fed back to participants. In this way, equal weight is
given to all those who participate and the risk of an indi-
vidual or group of individuals being overly influential or
dominant in the process is reduced [15].
Of the 227 COS studies published up to the end of
2014, 38 (17 %) included the use of Delphi surveys,
while the rate of use in ongoing studies appears to be
higher still. The majority of COS studies using Delphi
survey will use a modified rather than a traditional
Delphi. In a ‘traditional’ Delphi the outcomes of poten-
tial importance would be identified solely in the first
round of the Delphi through the use of an open text
question [16]. In modified Delphi surveys in COS devel-
opment, a ‘long list’ of outcomes is identified prior to
the Delphi survey, often, as noted above, through a sys-
tematic review of outcomes measured in previous trials.
However, a list of outcomes identified through such
systematic reviews may largely reflect outcomes that re-
searchers have thought important to measure, particu-
larly where trials predate the recent emphasis on patient
and public involvement (PPI) in the design. Patients,
carers and healthcare professionals might differ from
researchers in what outcomes they see as important.
Relying solely on systematic reviews of previous trials
may lead to outcomes that are important to patients and
other stakeholders being overlooked. Trialists need to
have confidence that the perspectives of all relevant
stakeholder groups have been heard and that their views
of important outcomes are incorporated into the Delphi
and, depending on the results of the Delphi, into the
final COS. To address this COS developers have recently
incorporated qualitative research into the development
process to help ensure that the outcomes in a COS are
important to the whole community of stakeholders, in-
cluding patients [13]. Often this has involved qualitative
data collection methods such as focus groups and one-
to-one interviews with patients, carers and healthcare
professionals [17, 18]. However, little methodological
guidance or precedent is available about how qualitative
research can best be used to inform this component of
COS development [19, 20].
Aim
This paper has two aims. First, we discuss the potential
roles for which primary qualitative research may be
used in the pre-Delphi stage of the development of a
COS. Second, we highlight considerations for conduct-
ing primary qualitative research in the pre-Delphi stage
of a COS development based on our experiences of
using qualitative research in three COS development
processes (Table 1).
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This paper is not intended to be prescriptive; rather it
looks to provide early guidance, which we hope will be
challenged, critiqued and built upon by others exploring
the role of qualitative research in COS development. We
conclude by identifying a number of areas where future
research may be beneficial to COS developers.
Results and Discussion
The discussions and advice provided in this paper are
based upon the experience of authors in developing
three COS in different research areas, with differing par-
ticipants and using different qualitative data collection
methods. Box 1 summarises the COS developments
which have been drawn upon.
The role of qualitative research in core outcome set
development
As noted above, qualitative research can be used in the
pre-Delphi stage of a COS development for a number
of purposes:
1. Identification of outcomes that are important to
stakeholders
Qualitative research allows COS developers to
explore the views of patients, healthcare
professionals and other stakeholders in order to
inform the development of a ‘long list’ of potential
outcomes. The discursive nature of qualitative
research enables participants to explain important
features of conditions and treatments in their own
terms rather than requiring them to engage with a
discourse of ‘outcomes’, which is likely to be
unfamiliar to those outside clinical research. If
conducted appropriately and rigorously the
qualitative research should afford stakeholders the
opportunity to explore and identify outcomes of
importance. In turn, this should promote COS
developers’ confidence that all potentially relevant
outcomes have been included in the first round of
the Delphi survey. In doing so, stakeholders have the
opportunity to set the agenda and potentially
identify outcomes that researchers may not have
anticipated. For example in mOMEnt, participants
emphasised psychological as well as social
consequences of impaired hearing, including
frustration and behavioural problems in children.
This contrasted with the limited reporting of these
outcome domains in the literature; of the 49 papers
identified in the mOMEnt systematic review, two
included outcomes related to psychosocial
development and six included outcomes related to
behaviour [21]
2. Facilitate understanding of not only which outcomes
are important, but crucially why they are important
Qualitative research with patients, carers and other
stakeholders can allow a greater understanding of
why an outcome is of importance. For example, in
PARTNERS2 employment was found to be an
Table 1 Description of studies used to inform this paper
PARTNERS2 [30] CONSENSUS [31] mOMEnt [32]
Study title Core outcome sets for use in effectiveness
trials involving people with bipolar disorder
and schizophrenia in a community-based
setting
CONSENSUS – squamous cell CarcinOma of
the oropharyNx: late phaSE cliNical trialS;
core oUtcomeS
mOMEnt – management of Otitis Media
with Effusion in cleft palate: protocol for a
systematic review of the literature and
identification of a core outcome set using a
Delphi survey
Qualitative
data
collection
method
Focus groups and one-to-one semi-
structured interviews, with prompts to
cover key discussion points. Topic guide
used as an aide memoire and iteratively
updated
One-to-one or three-way semi-structured in-
terviews with patients and their carers. The
topic guide comprised prompts to ensure
key topics were explored and was iteratively
developed
Conversational style interviews with parents
including prompts to discuss topics
identified from relevant literature.
Developmentally appropriate interviews
with children
Participants Bipolar disorder and schizophrenia service
user and their carers and healthcare and
research professionals working in this area
UK and US patients treated for oropharyngeal
squamous cell carcinoma (a type of head and
neck cancer) and their carers
Parents of children with non-syndromic cleft
palate (including cleft lip and palate) be-
tween 0 and 11 years of age, who had a
current or past diagnosis of OME, and chil-
dren themselves aged 6–11 years
Ethical
approval
Ethical approval for the study has been
sought and granted from the National
Research Ethics Service (NRES) West
Midlands – Edgbaston (reference number
14/WM/0052)
Ethical approval for this study was sought
and granted in the UK by the Liverpool
Central Research Ethics Committee
(reference 12/NW/0708). Approval at the
University of Texas MD Anderson Cancer
Center (Houston, TX, USA) was provided by
the Institutional Review Board (protocol
number 2013–0285)
Ethical approval for the qualitative
interviews with parents and children was
sought and granted by the National
Research Ethics Service – NRES North East
Committee – Greater Manchester East
(reference 11/NW/0586)
The PARTNERS2 COS development is part of a larger NIHR-funded project titled: PARTNERS2: Development and pilot trial of primary care-based collaborative care
for people with serious mental illness [33]. The mOMEnt COS development was part of a larger NIHR-funded project titled: The management of Otitis Media with
Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation [21]. The CONSENSUS study was conducted by Aoife Waters as part of
a PhD, supported by the Medical Research Council via the North West Hub for Trials Methodology Research
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important social outcome for many people
recovering from serious mental illness, and
was identified in both the literature review and
primary qualitative research. However, the
qualitative research allowed us to understand that
suitable employment was more important than
employment per se and that its importance
stemmed from the financial security, meaningful
role, structure to the day or the connectedness
which attending a workplace can allow. By
illuminating the context in this way, qualitative
research can ensure that meaningful and accurate
outcomes are taken forward into the Delphi survey
and brief yet informative descriptions to
accompany outcome names are developed to help
to ensure that participants can interpret a Delphi
survey. Furthermore, findings from qualitative
research may help to inform discussion at the
later consensus meeting (particularly if there are
disagreements among stakeholders), facilitating
agreement on the final set
3. Determining the scope of outcomes
Qualitative research may also allow the scope of
outcomes to be defined in a way which holds most
relevance to stakeholders in the Delphi. Take the
example of quality of life, which is a frequently
measured and reported outcome in trials. There are
numerous different conceptualisations of quality of
life that can be measured, varying from broad
definitions, such as global quality of life, capability or
well-being, to narrower definitions, such as health-
related quality of life or disease-specific quality of
life. Furthermore, within health-related quality of
life, there are subdomains of physical functioning
and psychological well-being. Qualitative research
can be used to delimit the scope of the domain and
ensure that the breadth of domain taken forward to
the Delphi is appropriate
4. Identification of appropriate language for use in a
Delphi survey
The language used to describe outcomes in clinical
trial publications may differ markedly from the
language used by patients, carers and other
stakeholders. Qualitative research that identifies and
describes outcomes using participants’ own
narratives can help COS developers to label and
describe outcomes in ways that make sense to the
stakeholders participating in the Delphi survey. This
is important to ensure a Delphi survey is accessible.
For example, based on qualitative findings the
research team may choose to describe the outcome
of isolation as ‘feeling cut off and distant from
friends’ or the outcome of aggression as ‘getting
wound up, angry or lashing out’
5. Comparison with other stakeholder data or
alternative sources of outcome data
Finally, outcomes derived from qualitative data
collected from different stakeholder groups, such
as service users, carers and healthcare professionals
can be compared within the study to understand
areas of discordance. When used in combination
with a systematic review of current outcomes this
can allow the COS developers to assess whether the
‘standard’ outcomes used in trials in that research
area are inclusive of the outcomes that stakeholders
think should be measured. Or, whether the
outcomes currently used in a research area may
be missing important domains and should be
supplemented when taken into round 1 of the
Delphi survey. For example, in PARTNERS2
‘symptoms’ was identified as an important outcome
by service users and carers, healthcare professionals
and through the review of literature. However, a
clear area of discordance was found whereby service
users emphasised ‘living with existing symptoms’ as
important, while the healthcare professional data
and the review data focused on ‘symptoms’
reduction’. In this case, both outcomes are being
taken into the Delphi, with correct terminology and
descriptions used to ensure the differences in the
two domains were evident to Delphi participants.
Deciding when qualitative research might not be needed?
As discussed above, qualitative research may allow the
views of a broad range of stakeholders to be included in
the development process of a COS and facilitate a move
away from researcher-only selected outcomes. However,
qualitative research can be resource-intensive; both in
terms of time and costs and the requirement for special-
ist input from qualitative experts. COS developers may
want to consider whether such work is needed in the
particular clinical area for which they are developing the
core set. Developers may want to consider the following
points: What is the level of PPI in the research area? If
there has been a high level of PPI input into relevant tri-
als and research studies, it may be reasonable to assume
that outcomes in the area already reflect the perspectives
of these stakeholders, although this may be challenged
on the grounds that PPI is not research. Developers
might also want to explore whether there are existing
qualitative datasets that could help to identify outcomes
of importance to stakeholders. If relevant studies have
been conducted in the area, it may be possible for these
data to inform the COS development through secondary
analysis. How challenging is the phrasing of outcomes in
the Delphi thought to be? For populations or areas
where participants are likely to be particularly sensitive
to the wording of outcomes, such as children or end of
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life care, the extra investment may be beneficial to en-
sure the wording is acceptable and appropriate. These
are some points which developers may want to consider;
however, this is not an exhaustive list and other consid-
erations may be important.
Challenges in using qualitative research to inform the
development of core outcome sets
Which stakeholders to include?
It is important to consider which stakeholders to include
as participants in qualitative research to best inform
COS development. Being a participant in a qualitative
study demands no prior knowledge of concepts such as
‘outcomes’, and no understanding of research processes
or the rationale for COS (see section below on discuss-
ing outcomes). Therefore, qualitative data collection
methods are appropriate when working with stakeholder
groups such as patients, carers and healthcare profes-
sionals for whom such topics may be unfamiliar.
Patients have valuable first-hand experience of living
with the illness and receiving treatments and knowledge
about which outcomes are important to them. Healthcare
and health research professionals may have experience of
treating a number of patients or observing a number of re-
search projects and, therefore, understand how an illness
manifests itself in different individuals or the different
treatment effects in individuals. Other stakeholders such
as carers, who are typically spouses or family members,
can provide useful perspectives as ‘involved witnesses’.
While our experience indicates that patients, carers
and professionals tend to identify some similar outcome
domains as important, there have also been some differ-
ences. For example, in PARTNERS2 when talking about
physical health outcomes patients identified broad areas
such as weight gain and reduced physical activity;
whereas professionals talked about specific clinical out-
comes, such as diabetes and blood pressure. Or, when
discussing social outcomes, such as being able to partici-
pate in a work environment, healthcare professionals
identified the ability to work as an important outcome;
whereas patients and carers identified subtly different
outcomes of participation in work that is appropriate to
their condition (e.g. flexible working), and participation
in a role that made them feel valued, as important
outcomes.
There are indications from the broader literature
that the differences we found between the outcomes
that stakeholders identify (and the added value of in-
cluding patients and carers) are widespread in this
type of study. Qualitative studies have found that pa-
tients may prioritise different outcomes to healthcare
professionals [22, 23] and may also identify additional
important outcomes [24].
Sampling
The pre-Delphi stage of the development of a COS
needs to identify outcomes that are relevant to all stake-
holders. A number of studies of qualitative outcomes
have reported difficulty accessing a broad range of par-
ticipants [17, 22, 24]. Therefore, it is important that the
sampling strategy facilitates access to patients, carers,
professionals and other participant groups who have
experience of the illness for which the COS is being de-
signed. If a key aim of pre-Delphi qualitative research is
to ensure no outcomes are overlooked, there is a strong
case for using a sampling strategy designed to identify a
maximum variation sample, as this would be more likely
to identify the wide range of outcomes of interest.
Purposive sampling can be used to recruit heteroge-
neous maximum variation samples, where people differ
by select characteristics [25]. This allows participants to
be selected based upon characteristics which might be
anticipated to influence the outcomes they perceive as
important [26, 27]. Parents of children of all ages in the
mOMEnt study identified hearing as an important out-
come. However, their concerns about hearing differed
between parents of preschool children (0–4 year-olds)
who focused on speech and language; parents of young
primary school children (5–7 year-olds) who emphasised
effects on social interaction; and parents of older
primary school children (8–11 year-olds) who were con-
cerned about social interaction and educational perform-
ance [21]. These differences highlight the importance of
including variation in a sample, in this case diversity of
age and development of children.
Qualitative samples are normally smaller in size than
quantitative samples, as quantification of incidence is
not the focus of this research. Rather the purpose is to
collect rich data that allows in-depth exploration and
understanding of different research questions [28]. Nor-
mally there will come a point of diminishing return
when new interview or focus group data cease to con-
tribute to the analysis, and the research team will decide
to stop data collection (the point of conceptual satur-
ation). In the PARTNERS2 interviews with healthcare
and research professionals this was noted after 14 inter-
views, with a further two interviews conducted to check
that data saturation had been reached. A larger sample
size may be required if particular diversity is needed in
some characteristics. For example, as well as sampling
participants from both the US and UK, the CONSENSUS
study aimed to include a diverse group of patients in
terms of sociodemographic, disease and treatment charac-
teristics and, therefore, recruited over 30 patients and
their carers. The mOMEnt study included a range of three
cleft malformation types (palate only or in combination
with either unilateral or bilateral cleft lip) and four treat-
ment pathways (ventilation tubes, hearing aids, both, or
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watchful waiting) resulting in a qualitative sample of 37
children.
Discussing trial outcomes
Qualitative research in the early phases of COS develop-
ment will be focused on identifying outcome domains
that are important to participants. Our experience sug-
gests that the concept of an outcome can be rather ob-
scure and challenging for patients, carers and other
stakeholders to engage with. Patients and carers cannot
be expected to be in a position to engage meaningfully
with questions such as ‘what outcomes do you think we
should measure in a trial of treatment for your illness?’
In the mOMEnt study parents did not respond readily
to the notion of ‘outcome’. Therefore, parents were
prompted to consider what they thought an intervention
should achieve (Table 2). Despite this two parents did not
distinguish between process (for example ‘good aftercare’)
and outcomes. In the PARTNERS2 we also found that
some healthcare professionals, researchers and commis-
sioners also struggled to discuss outcomes directly. Our ex-
perience is likely to be reflective of challenges experienced
by the broader research community, with a number of
studies reporting similar challenges [17, 22].
To address this, careful consideration needs to be
given to how outcomes are going to be elicited and dis-
cussed when designing qualitative research [29]. Nor-
mally this planning would involve consultation with
relevant patient groups in order to inform the design of
the research. Further consideration and consultation will
be needed when developing the topic guide or interview
schedule, when planning the prompts to be used and
when iteratively developing these over the course of
semi-structured interviewing to expand and explore par-
ticipants’ accounts. Encouraging a discussion of how an
illness has affected a person’s life, which parts of their
life they may perceive to have lost and what things they
hope to gain through treatment/care was found to be a
fruitful way of approaching the discussion in all three of
the studies used as examples in this paper. In CONSEN-
SUS one-to-one interviews allowed patients to provide a
chronological narrative of their lives as they underwent
treatment and beyond. Over the course of their inter-
views patients spoke of how outcomes that were import-
ant early in treatment sometimes differed to those that
became important at later stages. Interviews for the mO-
MEnt study commenced by inviting parents to tell the
story of their child’s otitis media with effusion (OME)
(or ‘glue ear’). These accounts provided narratives of the
context of experiences of the condition and interven-
tions and included implicit references to outcomes. As
the interview progressed the participants were asked to
discuss outcomes more explicitly. While in PARTNERS2
participants were encouraged to think back over how
their illness had changed their lives and to discuss their
goals in living with their condition. Later in the inter-
view participants were encouraged to think about these
changes and goals in terms of research outcomes. These
may be reflective of similar approaches taken by other
studies. For example, a qualitative study by Allard et al.
to identify key outcomes for children with neuro-
disability reported discussing outcomes by asking par-
ents and carers about ‘aspects of health’ and using a vis-
ual aid in the discussion with children [17]. Similarly a
qualitative study building the basis for a COS in
rheumatoid arthritis asked patients about how they
know when a intervention is working, what ‘returning to
normal’ meant to them and what makes them feel well
[22]. For all studies used as examples herein, allocating
time to these early discussions in focus groups and inter-
views helped to identify outcomes of relevance and
Table 2 Questions and prompts used by authors to discuss outcomes
Discussions with patients Discussions with healthcare/researcher professionals
PARTNERS2
‘I would like you to think about how your mental health problems have
changed your life and what you have lost because of them.’
‘This time rather than thinking about what you have lost, I would like
you think about what your goals are in living with your symptoms.’
‘Since your diagnosis and treatment has life changed for you? In what
ways has life changed?’
CONSENSUS
‘What’s a good day like for you? What’s a day like which is not so good’
‘What would you say your priorities are in life at the moment? What
would you have said if I’d asked that question before your illness and
treatment?’
mOMEnt – Discussion with parents: ‘What do you think grommets (VTs)
or hearing aids (HAs) should do for a child with glue ear?’
mOMEnt – Discussions with children: ‘What was “good” and “not so
good” about VTs or HAs?’
PARTNERS2
‘How does schizophrenia/bipolar disorder affect a person’s life? What do
they lose?’
‘What outcomes are you/should we looking to achieve when delivering
care or support to people with bipolar disorder/schizophrenia?’
‘What are you looking to improve in the person’s life?’
‘Are different outcomes important to patients at different stages in their
illness? At different stages in their health? Controlled versus stable?
Diagnosis versus later management?’
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provided the basis for later discussions about which of
the points discussed they felt were relevant to measure
as outcomes in a research setting.
Focus groups or interviews?
If the purpose of qualitative research prior to a Delphi
survey is to identify a complete list of outcomes which
may be important to stakeholders, then a data collection
method that allows the patient’s journey to be under-
stood may be most effective. However, if the purpose is
to define the scope of the outcomes or the language,
then an approach that allows convergences and diver-
gences between different stakeholders to be identified
may be most appropriate. However, often the objective
of pre-Delphi qualitative research is to inform both a
complete list and increase understanding of outcomes,
which may call for a mix of qualitative data collection
methods. Focus groups and one-to-one interviews are
two ways in which qualitative data can be collected.
These two methods of data collection have important
differences which need to be considered when identify-
ing outcomes in COS development.
In a one-to-one interview, data are generated through
an interaction between the interviewer and the partici-
pant. A semi-structured format helps to ensure that the
most important aspects are covered, while allowing the
participant flexibility to explore concepts important to
them. As described above this may involve participants
giving an account of their illness and treatment experi-
ence, which researchers can interpret to identify out-
comes which are important to patients.
In a focus group, data are generated through an inter-
action between the participants which is facilitated by
the researcher. Participants are in a position to listen,
discuss, agree, question or clarify points that are raised
by other participants in the group. This synergistic
discussion aims to facilitate participants in exploring
outcomes which are important to them or the people
they care for. Group discussion can help patients to see
how their experiences differ to those of other partici-
pants in the groups and thereby help to identify out-
comes which are important to them, or to challenge
outcomes which are not important to them. However,
there are drawbacks too. The logistics of completing
groups can be challenging. Just as some people will dis-
like the idea of participating in an individual interview
and prefer being part of a group, others may perceive a
group discussion as intimidating and inhibitive. Add-
itionally, a typical focus group involving 8–9 participants
and lasting 90–120 minutes provides each individual
with an average of only 10–15 minutes of speaking time,
which can constrain the range of outcomes discussed.
Our experience of using focus groups in COS develop-
ment indicates that while outcomes were discussed in
depth, fewer outcomes were identified and understand-
ing the patient journey and outcomes of importance at
different stages was difficult. To address this challenge
in PARTNERS2 we used a number of methods to collect
non-verbal data, where participants were given the
opportunity to write down outcomes of importance to
them on slips of paper or ‘post-it’ notes. These data were
then either used to inform discussion later in the focus
group or were collected solely as written data. In some
instances this exercise was designed to hide the identity
of the note’s author to allow sensitive outcomes to be
identified and subsequently discussed without embar-
rassment or inhibition.
Analysis of data
When analysing the data from a qualitative study to sup-
port COS development, a focus must be maintained
upon the particular purpose of the research. If, as de-
scribed above, the main purpose of the research is three-
fold (to identify outcomes, define the scope of outcomes
and identify common language) this must be reflected in
the analysis. In many cases analytical approaches that
code, label and index data will facilitate the process of
identifying relevant outcome domains for the Delphi.
Paying attention to, and maintaining the language of, the
study participants will allow identification of common
language. This should be part of an interpretive process
whereby analysts consider the data as a whole in identi-
fying relevant and understandable outcomes.
In the CONSENSUS study, for example, the coding,
labelling and indexing of data, allowed the identification
of the fact that patients tended to talk at length about
the impact of treatment on aspects of their quality of life
and how in contrast, survival was often mentioned only
in passing or indirectly. One interpretation might be that
survival was less important to these patients than as-
pects of their quality of life. However, considering the
data and the interview as a whole the CONSENSUS
team’s interpretation was that issues of life and death
were difficult for patients to talk about. In the context of
interviews where patients were describing the months of
unpleasant treatment that they had endured to improve
their chances of surviving the illness, the importance of
survival did not need to be laboured.
Future research
The use of qualitative research in the development of
COS is increasing. This paper has described the poten-
tial benefits of qualitative research, indicated some of
the challenges faced and provided examples of methods
which may help to overcome them. The advice and guid-
ance provided in this paper, which is not intended to be
prescriptive, is based largely on the authors’ experiences
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of using qualitative research in the context of wider
COS development projects. A better understanding of
the role and contribution of qualitative research in COS
development will depend on future methodological re-
search. The following areas are identified as in particular
need of such research.
Methods of data collection
More knowledge is needed on the differences in data
collected from one-to-one interviews versus those col-
lected from focus groups. As noted above our experience
suggests that differences may arise; however, the nature
and impact of differences on what is learnt and the
associated resource use is not clear without further ex-
ploration. By reflecting on the use of qualitative data
collection methods in COS development exercises to
date, future research can be designed to assess whether
interview and focus group data yield the same depth of
meaning and understanding about stakeholder preferred
outcomes and the extent and implications of any differ-
ences. Of course this cannot be considered in isolation
from the points below.
Discussing outcomes
The way that outcomes are introduced to research partici-
pants and the framing of the discussion that follows will
likely have a notable impact upon data collected. Research
into the best ways to discuss outcomes with patients,
carers and healthcare professionals – and whether to
avoid overt discussions of ‘outcomes’ altogether – would
help to ensure that participants are able to fully contribute
to COS development process [29].
Analysing data
It is essential to understand the approaches to qualitative
analysis that will be most informative for COS develop-
ment. The need to go beyond a simple cataloguing of
outcomes to form a deeper understanding of what par-
ticipants wanted from treatments was identified in each
of the COS development examples provided here.
Sampling
Understanding the impact of different sampling tech-
niques is essential. As noted above, based on our experi-
ence, maximum variation sampling seems to be most
likely to identify potentially important outcomes. How-
ever, confirmation of this and the potential effects of
convenience or opportunistic sampling is vital.
Use of existing qualitative research
There is a large and expanding qualitative research lit-
erature on a wide range of different conditions and treat-
ments and there are likely to be several such studies in
particular disease areas that could potentially contribute
to COS development, or even avoid the need to collect
new qualitative data, which can be resource-intensive.
Where qualitative datasets are available, secondary ana-
lysis of these may similarly negate the need for primary
data collection, although research is needed to examine
the extent to which such data, which will likely have
been collected for very different purposes, can be used
to inform COS development. Future research about how
to usefully incorporate these data into COS development
is of importance.
Conclusion
The use of qualitative research in the pre-Delphi stage of
COS development is a novel methodological advance
which brings a number of potential benefits. These ben-
efits all relate to the primary goal of ensuring that all
stakeholder perspectives are represented in the final
COS, whether through identification of outcomes, un-
derstanding the importance of outcomes or identifying
patient and carer language. Our experience suggests that
with these benefits come a number of challenges. This
paper suggests a number of potential methodological
solutions, which we hope will be investigated further by
researchers in this field.
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